R&D AT HOUSEY PHARMA
Cancer is a disease that results from a series of oncogenic events that culminate in irreparable genetic damage to normal cells. These events ultimately give rise to the uncontrolled, invasive cellular growth termed malignant cancer. Together with collaborators, our company has identified key target proteins that are involved both initially as well as in the later stages of growth of certain forms of human cancer. These target proteins remain functional when patients relapse after being treated with an initially effective drug regimen. Our findings suggest powerful new strategies for identifying new molecular entities that will interact with these target proteins and help to overcome the ability of advanced forms of cancer to resist effective drug treatment.
Diabetes is a disease that has reached epidemic proportions in the western nations of the world. It has been estimated that one of every five people born after the year 2000 will develop diabetes in their lifetime. More than 16 million Americans already suffer from this disease. Diabetes is manifest by the loss of the ability to control the amount of sugar (glucose) present in the blood.
Normal control of blood glucose is essential for good health and well-being. Blood glucose levels are maintained within certain limits as a result of the effects of a hormone called Insulin on various tissues and organs in the body. If the concentration of blood glucose strays outside of the normal limits, as it does in untreated diabetes, serious and sometimes fatal consequences can occur. Insulin is produced by specialized cells called “ß-cells” that are located in the pancreas.
There are two major subtypes of diabetes: Type I and Type II Diabetes
Housey Pharma is working to develop novel treatments for both Type I and Type II Diabetes.
Type I diabetes accounts for about 5% of all diabetes cases. Type I, also known as “insulin-dependent” diabetes, occurs primarily in children and young adults. This form of diabetes results when a person’s immune system destroys the insulin-producing beta cells by mistake. Once the insulin-producing ß-cells have been lost, the person loses the ability to make sufficient amounts of insulin and diabetes results.
Type II diabetes, which accounts for 90-95% of all diabetes cases, occurs when a patient's ß-cells are unable to produce enough insulin to compensate for the insulin resistance that has developed and matured in various tissues and organs in their bodies, including muscle, liver and surrounding organs.
We are pursuing the creation and development of compounds that are capable of enlarging the population of ß-cells present in diabetic patients, thereby reducing their overall therapeutic requirements. The goal is to reduce or eliminate their dependence upon insulin injections altogether by substituting insulin with an orally active medicine that is more effective, less expensive, and easier to administer than supplemental insulin injections.
Based upon experimental research beyond the scope of this general discussion, HPRL believes that compounds capable of stimulating the certain proteins present in ß-cells will result in the regeneration (i.e. re-growth) of residual beta cells that remain present in diabetic patients. Such compounds may also stimulate precursor cells to differentiate into ß-cells. Once such cells are stimulated to grow to a sufficient extent, we believe that the diabetic patient’s symptoms will resolve and normal control of blood sugar will resume